• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Thursday, August 11, 2022
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

‘Buy’ on Cipla; firm likely to beat its cost-saving targets

by The Outlooker Web Desk
November 15, 2020
in Business
0
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

Cipla share at 8% of Albuterol market, gradual gains from here.

Cipla posted a 6%/4% beat on revenue/Ebitda despite the US revenues being in line. The beat was driven by higher sales in India and Emerging markets. Covid products now account of 5% of India sales and company also saw a healthy uptick in trade generics. Cipla has added Remdesivir capacities with the help of third party manufacturers. Additonally, company is likely to beat its cost saving targets. We upgrade FY21E/22E EPS estimates by 9%/12%. Buy. Top Pick.

Cipla share at 8% of Albuterol market, gradual gains from here. Cipla US revenues were in line with our estimates. On the call, management said that while they have the capacity, they are looking at a sustainable market share with a high inventory at hand. Company pointed to challenges of sustained manufacturing in a complex high volume product. As a result, they have not rushed to grab market share even after Perrigo’s exit. Management didn’t commit to a target market share, but it appears to us that any market share gains from here will be small. As our colleague David Steinberg states here, Perrigo will likely make it back to market in 2021.

From that perspective, it makes sense for Cipla to avoid a market share scramble with Lupin and Perrigo ramping up over next quarters.

US margins have turned around due to Albuterol, now in line with company margins. Previously, company had stated that the US business was at breakeven level. However, Albuterol has provided the company with sustainable profitability, even after factoring in R&D costs. Albuterol HFA inhaler is a fairly competitive category and re-entry of Perrigo will place 6 generics in the market. This will possibly deter further competition given the upfront costs of project including capex and R&D.

Among other product news, Cipla is API supplier to Teva’s gTruvada (First to market, recently launched) but doesn’t consider it to be a large opportunity.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
Barack Obama’s Remark On Rahul Gandhi Distasteful, Says Shiv Sena’s Sanjay Raut

Maharashtra Coronavirus News, Temples Reopening: Not Victory Of Hindutva

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

3 Lashkar Terrorists Shot Dead In Jammu And Kashmir’s Budgam
National

3 Lashkar Terrorists Shot Dead In Jammu And Kashmir’s Budgam

August 10, 2022
Justice Uday Umesh Lalit Appointed As 49th Chief Justice Of India
National

Justice Uday Umesh Lalit Appointed As 49th Chief Justice Of India

August 10, 2022
Pawar accuses BJP of finishing off regional allies, backs Nitish Kumar for snapping ties with saffron party
Politics

Pawar accuses BJP of finishing off regional allies, backs Nitish Kumar for snapping ties with saffron party

August 10, 2022
Sworn in as CM for eighth time, Nitish tells BJP to 'worry' about 2024 LS polls
Politics

Sworn in as CM for eighth time, Nitish tells BJP to 'worry' about 2024 LS polls

August 10, 2022

Connect with us

No Result
View All Result

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • 3 Lashkar Terrorists Shot Dead In Jammu And Kashmir’s Budgam
  • Justice Uday Umesh Lalit Appointed As 49th Chief Justice Of India
  • Pawar accuses BJP of finishing off regional allies, backs Nitish Kumar for snapping ties with saffron party

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.